Role of formulations in targeted delivery of m/RNA for vaccines, therapeutics and in vivo gene editing
The expanding scope of mRNAbased therapeutics and vaccines has brought formulation science to the forefront, particularly in enabling targeted, effective, and safe delivery. In a focused session at the FDD Conclave 2025, this critical intersection was explored under the session titled ‘Role of formulations in targeted delivery of m/RNA for vaccines, therapeutics and in vivo gene editing.’
Presented by Dr Ramesh Matur, Senior VP and Head of the Vaccines R&D Division at Biological E, the session offered deep insights into how advances in formulation technologies are shaping the future of RNA-based medicine. With an emphasis on both scientific innovation and strategic opportunity, the talk addressed the evolving needs of global healthcare through the lens of delivery platforms.
Central to the discussion was the role of lipid nanoparticles (LNPs), which have emerged as the preferred non-viral vectors for delivering mRNA. Dr Matur detailed their ability to shield fragile RNA molecules, navigate biological barriers, and enable efficient cellular uptake has made them instrumental in the success of current mRNA vaccines and holds equal promise for gene editing and therapeutic applications.
As the demand for precision delivery systems grows, the refinement of LNP-based platforms continues to be a major driver of innovation. Beyond the science, Dr Matur also highlighted India’s potential to play a pivotal role in this space. With a strong foundation in chemistry, biology, and computational sciences, Indian researchers are well-positioned to contribute meaningfully to the global RNA landscape.
The integration of these disciplines can accelerate the development of novel delivery systems and biomolecular platforms, while also enabling the creation of intellectual property around rare and unmet disease areas.
Dr Matur concluded the session by underscoring the importance of leveraging India’s scientific strengths to not only advance therapeutic possibilities but to also shape the future of personalised, formulation-driven medicine.